Please find information below about the 2019 ASCO Annual Meeting, which will take place Friday, May 31 - Tuesday, June 4, 2019, at McCormick Place in Chicago, IL. If you are a public relations professional looking for meeting information, please see our For PR Professionals page.
- Hotel reservation deadline: Wednesday, April 24
- Embargoed presscast for credentialed media: Wednesday, May 15
- Final deadline for pre-registration: Friday, May 17
- 2019 ASCO Annual Meeting: Friday, May 31 - Tuesday, June 4
Register to Attend the Meeting in Person/Access Embargoed Materials
Visit ASCO's Media Headquarters to apply for media credentials, register to attend the meeting, access embargoed meeting information, and locate presscast dial-in information. For questions about how to navigate the site, please contact ASCO Media Registration. The pre-registration deadline for the 2019 ASCO Annual Meeting is Friday, May 17. Registrations submitted after this date will not be processed.
- Meeting website
- Press briefing schedule
- Meeting program
- Abstract embargo and release information
- Abstract announcements and exceptions
Press Program Announcement:
ASCO Announces Top Studies to Be Presented at 2019 Annual Meeting
ALEXANDRIA, Va. – Cancer experts from around the world will gather to share the latest clinical cancer research impacting patient care at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO). Advances in targeted therapies for pancreatic, prostate, and pediatric cancers, as well as new approaches to overcoming limited access to cancer care are among the topics that will be highlighted in the meeting’s official Press Program. Read the full release.
May 15 Presscast:
- Balanced, Low-Fat Diet Reduces Risk of Death From Breast Cancer in Postmenopausal Women
ALEXANDRIA, Va. – The federally funded Women’s Health Initiative (WHI) clinical trial of dietary modification in nearly 49,000 postmenopausal women with no previous history of breast cancer reported that women who followed a balanced diet that was low in fat and included daily servings of fruits, vegetables, and grains had a 21% lower risk of death from breast cancer than women in the control group who continued their normal diet, which was higher in fat overall. Read the full release.
- Pediatric MATCH Trial Finds More Frequent Targetable Genetic Alterations in Pediatric Cancers Than Predicted
ALEXANDRIA, Va. – At the launch of the National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (NCI-COG Pediatric MATCH) trial in 2017, it was estimated that tumor sequencing in children, adolescents, and young adults with treatment-refractory cancers – cancers that do not respond to treatment– would identify genetic alterations that matched an investigational targeted therapy in 10% of study participants. Read the full release.
- Entrectinib Produces Responses in Children and Adolescents With CNS and Other Cancers That Have Specific Gene Fusions
ALEXANDRIA, Va. – In a phase I/IB study of 29 patients, age 4.9 months to 20 years, with rare central nervous system tumors, neuroblastoma, or other solid tumors, responses to entrectinib, a novel targeted treatment, were seen in 12 of the 28 evaluable patients. Read the full release.
- Low-Dose Chemotherapy Regimen Effective in Older and Frail Patients With Gastroesophageal Cancer
ALEXANDRIA, Va. – The phase III GO2 randomized trial of 514 older and frail people in the United Kingdom with advanced gastroesophageal cancer found that the lowest tested dose of oxaliplatin (Eloxatin) and capecitabine (Xeloda) was comparable to the highest dose in terms of delaying disease progression and minimizing side effects. Read the full release.
- Lenalidomide Reduces Risk That Precancer Myeloma Will Progress to Overt Multiple Myeloma in High Risk Individuals
ALEXANDRIA, Va. – The phase II/III E3A06 randomized clinical trial found that lenalidomide (Revlimid) significantly reduces the risk of smoldering multiple myeloma (SMM) -- a precancerous condition -- from progressing to cancer in patients at moderate or high-risk. Read the full release.